These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 38228572)

  • 21. Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.
    Hélène C; Conrad O; Pflumio C; Borel C; Voegelin M; Bernard A; Schultz P; Onea MA; Jung A; Martin S; Burgy M
    BMC Cancer; 2023 Dec; 23(1):1209. PubMed ID: 38066522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
    Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
    Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach.
    Chamseddine AN; Assi T; Mir O; Chouaib S
    Pharmacol Ther; 2022 Mar; 231():107986. PubMed ID: 34481812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
    Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
    Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
    Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
    Front Immunol; 2021; 12():638763. PubMed ID: 34305884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiotherapy-induced tumor physical microenvironment remodeling to overcome immunotherapy resistance.
    Peng J; Yin X; Yun W; Meng X; Huang Z
    Cancer Lett; 2023 Apr; 559():216108. PubMed ID: 36863506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
    Sasidharan Nair V; Elkord E
    Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters.
    Wang S; Xie K; Liu T
    Front Immunol; 2021; 12():690112. PubMed ID: 34367148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors.
    An HJ; Chon HJ; Kim C
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines.
    Oladejo M; Paulishak W; Wood L
    Semin Cancer Biol; 2023 Jan; 88():81-95. PubMed ID: 36526110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
    Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies.
    Atkins MB; Ascierto PA; Feltquate D; Gulley JL; Johnson DB; Khushalani NI; Sosman J; Yap TA; Kluger H; Sullivan RJ; Tawbi H
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy.
    Sadeghirad H; Liu N; Monkman J; Ma N; Cheikh BB; Jhaveri N; Tan CW; Warkiani ME; Adams MN; Nguyen Q; Ladwa R; Braubach O; O'Byrne K; Davis M; Hughes BGM; Kulasinghe A
    Front Immunol; 2023; 14():1135489. PubMed ID: 37153589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors.
    Wang D; Chen X; Du Y; Li X; Ying L; Lu Y; Shen B; Gao X; Yi X; Xia X; Sui X; Shu Y
    Front Immunol; 2022; 13():799988. PubMed ID: 35281032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need.
    Hu-Lieskovan S; Malouf GG; Jacobs I; Chou J; Liu L; Johnson ML
    Future Oncol; 2021 Apr; 17(11):1401-1439. PubMed ID: 33475012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.
    Bagchi S; Yuan R; Engleman EG
    Annu Rev Pathol; 2021 Jan; 16():223-249. PubMed ID: 33197221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors.
    Chen JA; Ma W; Yuan J; Li T
    Cancer Treat Res; 2020; 180():251-279. PubMed ID: 32215873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies.
    Hernandez C; Arasanz H; Chocarro L; Bocanegra A; Zuazo M; Fernandez-Hinojal G; Blanco E; Vera R; Escors D; Kochan G
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.
    Petrova V; Arkhypov I; Weber R; Groth C; Altevogt P; Utikal J; Umansky V
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32235439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of regulatory T-cells in cancer immunotherapy: therapeutic relevance of immune checkpoint inhibition.
    Singh R; Srivastava P; Manna PP
    Med Oncol; 2024 Jan; 41(2):59. PubMed ID: 38238513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.